The Early Breast Cancer Trialists meta-analysis have shown that the addition of chemotherapy does not offer significant benefit but exposes toxicity from cytotoxic chemotherapy in a majority of patients with ER-positive/human epidermal growth factor receptor2 (HER2)-negative tumors [3, 4]. This evidence concerns the gene ERBB2 and breast cancer.